TRAUMA
AAOS: Indomethacin does not prevent heterotopic ossification
98 patients with acetabular fractures who underwent surgical fixation were randomized into four groups to determine the abundance of heterotopic ossification, non-union, and differences in pain and function with varying durations of indomethacin treatment. The first Group consisted of a placebo for 6 weeks, group 2 consisted of 3 days of indomethacin followed by placebo for a total of 6 weeks, group 3 consisted of 1 week of indomethacin followed by 5 weeks of placebo, and group 4 consisted of 6 weeks of indomethacin treatment. After 1 year of evaluation, indomethacin did not affect the incidence or volume of clinically significant heterotopic ossification and increased the symptomatic non-union of posterior wall according to VAS pain and CT scans.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
